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Purpose
High microsatellite instability (MSI) is related to good prognosis in gastric cancer. We aimed 
to identify the prognostic factors of patients with recurrent gastric cancer and investigate 
the role of MSI as a prognostic and predictive biomarker of survival after tumor recurrence. 
Materials and Methods
This retrospective cohort study enrolled patients treated for stage II/III gastric cancer who 
developed tumor recurrence and in whom the MSI status or mismatch repair (MMR) status 
of the tumor was known. MSI status and the expression of MMR proteins were evaluated 
using polymerase chain reaction and immunohistochemical analysis, respectively.   
Results
Of the 790 patients included, 64 (8.1%) had high MSI status or MMR deficiency. The 
tumor-node-metastasis stage, type of recurrence, Lauren classification, chemotherapy 
after recurrence, and interval to recurrence were independently associated with survival 
after tumor recurrence. The MSI/MMR status and receiving adjuvant chemotherapy were 
not associated with survival after recurrence. In a subgroup analysis of patients with high 
MSI or MMR-deficient gastric cancer, those who did not receive adjuvant chemotherapy 
had better treatment response to chemotherapy after recurrence than those who received 
adjuvant chemotherapy.  
Conclusion
Patients with high MSI/MMR-deficient gastric cancer should be spared from adjuvant 
chemotherapy after surgery, but aggressive chemotherapy after recurrence should be con-
sidered. Higher tumor-node-metastasis stage, Lauren classification, interval to recurrence, 
and type of recurrence are associated with survival after tumor recurrence and should thus 
be considered when establishing a treatment plan and designing clinical trials targeting 
recurrent gastric cancer.    
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Introduction
Gastric cancer is among the leading causes of cancer-
related death worldwide [1,2]. Surgery and additional 
chemotherapy with and without radiation therapy are the 
standard treatment modalities for curative intent of locally 
advanced gastric cancer [3]. However, over 40% of patients 
treated with surgery and additional chemotherapy develop 
tumor recurrence that results in mortality [3,4]. Consequent-
ly, the prognostic factors of survival after recurrence (SAR) 
are clinically important in the treatment of gastric cancer. 
Nonetheless, only few studies have addressed this issue in 
Cancer Res Treat. 2020;52(4):1153-1161
gastric cancer [4,5].
Recent studies on the biology of gastric cancer [6-8] have 
identified predictive biomarkers of prognosis and chemo-
therapy response [8-10]. Microsatellite instability (MSI) 
is one such biomarker. MSI-high (MSI-H) is known to be 
related to good prognosis and no benefit or even harmful 
effect from additional chemotherapy after surgery for stage 
II/III gastric cancer [4,11,12]. These clinical characteristics 
imply that surgery alone would be an effective strategy for 
patients with MSI-H gastric cancer. However, some patients 
with MSI-H still experience tumor recurrence, and thus, 
clinicians hesitate while forgoing additional chemotherapy 
because of the fear that no chemotherapy may increase the 
risk of tumor recurrence [13]. It is unclear whether chemo-
therapy after recurrence yields a similar benefit between 
gastric cancer patients who did and did not receive postop-
erative chemotherapy before recurrence [5,14], particularly 
according to the MSI status. Thus, this study aimed to iden-
tify prognostic factors of patients with recurrent gastric can-
cer and investigate the role of the MSI status as a prognostic 
and predictive biomarker of SAR.  
Materials and Methods
1. Population
Two large cohorts, namely the Y-cohort and S-cohort, 
were included in this study. The Y-cohort was based on the 
population of a previous study that reported the clinical 
implication of the MSI status for stage II/III gastric cancer 
[15], while the S-cohort was based on the population of pre-
vious studies on various biomarkers and molecular markers 
[7]. All patients underwent gastrectomy for curative intent 
and were pathologically confirmed to have stage II or III 
gastric cancer according to the 8th edition of the American 
Joint Committee on Cancer [16]. The additional chemo-
therapy and follow-up strategy were employed according 
to the guidelines [17,18]. We included patients with tumor 
recurrence and in whom the MSI or mismatch repair (MMR) 
status was known. Patients who received chemotherapy or 
radiation therapy before surgery and whose primary can-
cer was in the remnant stomach were excluded. Patients in 
whom the cancer was in the remnant stomach after initial 
gastrectomy but were treated via surgery with curative 
intent were also excluded. 
2. Clinicopathologic variables 
We retrospectively reviewed the clinicodemographic 
characteristics, including sex and age during initial gastric 
cancer diagnosis, presence of serosa invasion and lymph 
node metastasis, TNM stage, Lauren classification, loca-
tion of tumor, MSI/MMR status, whether or not the patient 
received adjuvant chemotherapy, type of recurrence, inter-
val between initial gastrectomy to tumor recurrence (< 1 
year, ≥ 1 year and < 2 years, ≥ 2 years), and whether or not 
the patient received chemotherapy after recurrence. The 
type of recurrence was classified as locoregional, hematog-
enous, peritoneum, any combination, and ovarian metasta-
sis only. Recurrence and survival were determined based on 
records from the hospital and the Korean National Statisti-
cal Office and through telephone surveys. 
3. Definition of MSI and MMR
The MSI status was evaluated in the Y-cohort using pol-
ymerase chain reaction (PCR). DNA was extracted from 
paired normal tissue and tumor tissue that were formalin-
fixed, paraffin embedded, and amplified using PCR for two 
mononucleotide repeat markers (BAT25 and BAT26) and 
three dinucleotide markers (D5S346, D2S123, and D17S250) 
[19]. MSI-H was defined as an instability at two or more 
markers; otherwise, it was defined as microsatellite stable 
(MSS).
The expression of MMR proteins was evaluated in the 
S-cohort via immunohistochemical (IHC) analysis. Sam-
ples from tissue microarray blocks were used to prepare 
3- to 4-μm-thick sections for analysis, and monoclonal anti-
bodies, including mouse anti-MLH1 (#PA0610, Leica Bio-
system, Buffalo Grove, IL), mouse anti-MSH2 (#286M-16, 
Cell Marque, Rocklin, CA), mouse anti-MSH6 (#610919, 
BD Transduction, San Jose, CA), and rabbit anti-PMS2 
(#288M-16, Cell Marque), were used for staining. Deficient 
MMR (dMMR) was defined as loss of any MMR protein 
expression in ≥ 80% of tumor cells while internal control 
nuclei (lymphocytes and stromal cells) are stained [20]. Two 
pathologists independently performed the evaluations. 
4. Statistical analysis
Statistical analysis was performed using SPSS ver. 20.0 
for Windows (IBM Corp., Armonk, NY) and R software ver. 
3.4.3. Categorical variables are described as numbers and 
proportions and were compared using a chi-square test. 
Continuous variables are described as mean with standard 
deviation and were compared using an independent t test. 
Patient prognosis was evaluated according to SAR, which 
was defined as the time from recurrence to death due to any 
cause. The SAR of each group was generated using Kaplan-
Meier curves and compared using log-rank test. A Cox pro-
portional hazard model was used with the hazard ratio (HR) 
and its 95% confidence interval (CI). Institution was used as 
the adjustment variable for the overall analysis. Subgroup 
analysis was conducted with respect to each institution. The 
final multivariable model comprised variables that were 
statistically significant in the univariable analysis and were 
selected using likelihood forward methods. A two-sided 
p-value of < 0.05 was considered statistically significant. 
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5. Ethical statement
This study was approved by the Institutional Review 
Board (approval number 4-2019-0244), and the need for 
informed consent was waived.
Results
1. Baseline characteristics of the patients, initial gastric 
cancer stage, and treatment
The overall cohort comprised 790 patients (439 and 351 
patients from the Y-cohort and the S-cohort, respectively); 
of these, 65.9% were men. In total, 602 patients (76.2%) were 
treated for stage III gastric cancer. With respect to Lauren 
histology, 293 (37.1%) and 497 (62.9%) patients had an intes- 
tinal and diffuse/mixed type, respectively. There were 64 
patients with MSI-H/dMMR gastric cancer (8.1%), and 570 
patients (72.7%) received adjuvant chemotherapy after gas-
trectomy. Over 70% of patients developed tumor recurrence 
within 2 years after initial surgery; the most common type 
was peritoneal recurrence (42.5%). Furthermore, 64.9% of 
patients were administered chemotherapy after tumor recur- 
rence (Table 1). The proportion of serosa-positive cases, 
MSI-H/dMMR cases, and cases treated with both adjuvant 
and post-recurrence chemotherapy; TNM stage; interval to 
recurrence; and type of recurrence were significantly differ-
ent between the Y-cohort and S-cohort (S1 Table). 
Consequently, institution was used as an adjustment vari-
able in the following analysis. The type of recurrence was 
similar between MSI-H/dMMR and MSS/proficient MMR 
(pMMR) tumors (S2 Table).
2. Factors related to prognosis after recurrence
In the overall population, age (adjusted HR, 1.007; 95% CI, 
1.011 to 1.013; p=0.025), serosa invasion (adjusted HR, 1.324; 
95% CI, 1.128 to 1.555; p=0.001), TNM stage (adjusted HR, 
1.288; 95% CI, 1.086 to 1.527; p=0.004), Lauren classification 
(adjusted HR, 1.470; 95% CI, 1.264 to 1.708; p < 0.001), chem-
otherapy after recurrence (adjusted HR, 0.363; 95% CI, 0.306 
to 0.431; p < 0.001), interval from surgery to recurrence (p < 
0.001), and type of recurrence (p < 0.001) were significantly 
associated with SAR (Table 2); in contrast, sex, presence of 
lymph node metastasis, location of tumor, and receiving 
adjuvant chemotherapy were not. The associations between 
clinicopathologic variables, except MSI/MMR status, and 
SAR were similar in both cohorts (S3 Table). 
In the overall cohort, MSI-H/dMMR was not associa-
ted with SAR (adjusted HR, 1.155; 95% CI, 0.885 to 1.506; 
p=0.290) (Table 2, S4A Fig.). However, in the subgroup 
analysis by institutions, MSI-H was related to poor SAR in 
the Y-cohort (HR, 1.544; 95% CI, 1.038 to 2.298; p=0.032) (S3 
Table, S4B Fig.), while there were no significant differences 
in SAR according to the MMR status in the S-cohort (HR, 
0.950; 95% CI, 0.667 to 1.354; p=0.777) (S3 Table, S4C Fig.). In 
the institution-adjusted multivariable analysis, TNM stage, 
Lauren classification, interval to recurrence, type of recur-
rence, and chemotherapy after recurrence were independ-
ent factors related to SAR (Table 3). 
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Table 1.  Clinicopathologic characteristics of the patients, initial 
gastric cancer stage, and treatments
Characteristic No. (%) (n=790)
Age, mean±SD (yr) 57.18±12.53
Sex 
    Male 521 (65.9)
    Female 269 (34.1)
Serosa invasion 
    Negative 355 (44.9)
    Positive 435 (55.1)
LN metastasis 
    Negative 64 (8.1)
    Positive 726 (91.9)
TNM stage 
    II 188 (23.8)
    III 602 (76.2)
Lauren classification 
    Intestinal 293 (37.1)
    Diffuse/Mixed 497 (62.9)
Tumor location  
    UB/Whole 133 (16.8)
    MB/LB 657 (83.2)
MSI/MMR 
    MSS/pMMR 726 (91.9)
    MSI-H/dMMR 64 (8.1)
Adjuvant CTxa) 
    No 214 (27.3)
    Yes 570 (72.7)
Interval to recurrence (yr) 
    < 1  322 (40.8)
    ≥ 1, < 2 237 (30.0)
    ≥ 2 231 (29.2)
Type of recurrence 
    Locoregional 132 (16.7)
    Hematogenous 154 (19.5)
    Peritoneum 336 (42.5)
    Any combination 142 (18.0)
    Krukenberg only 26 (3.3)
CTx after recurrencea) 
    No 265 (35.1)
    Yes 489 (64.9)
LN, lymph node; UB, upper body; MB, mid-body; LB, lower body; 
MSI, microsatellite instability; MMR, mismatch repair; MSS,  
microsatellite stable; pMMR, proficient mismatch repair; MSI-H, 
microsatellite instability high; dMMR, deficient mismatch repair; 
CTx, chemotherapy. a)Information was incomplete in some patients 
because of transfer to other hospital, loss of follow-up, and  
unclear medical records. 
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3. Effect of chemotherapy according to MSI/MMR status
Additional analyses were conducted to evaluate the 
effects of adjuvant chemotherapy and chemotherapy after 
recurrence in the overall cohort and according to the MSI/
MMR status. In the overall cohort, patients who received 
chemotherapy after recurrence had longer SAR regardless 
of whether or not they received adjuvant chemotherapy 
(log-rank p < 0.001) (Table 4, Fig. 1A), and a similar find-
ing was noted in both cohorts (log-rank p < 0.001 and p < 
0.001 in the Y-cohort and S-cohort, respectively) (S5A and 
S5B Fig.). A similar finding was observed in MSS/pMMR 
tumors of overall cohort and in both cohorts (Fig. 1B, S6A 
and S6B Fig.).
Among patients with MSI-H/dMMR tumors, those who 
Table 2.  Univariable Cox proportional hazard model for survival after recurrence
                                                         Overall cohort
 Adjusted HRa) (95% CI) p-value
Age  1.007 (1.001-1.013) 0.025
Sex  0.362
    Male 1 ( 
    Female 1.072 (0.923-1.246) 
Serosa invasion  0.001
    Negative 1 ( 
    Positive 1.324 (1.128-1.555) 
LN metastasis  0.325
    Negative 1 ( 
    Positive 1.141 (0.878-1.482) 
TNM stage  0.004
    II 1 ( 
    III 1.288 (1.086-1.527) 
Lauren classification  < 0.001
    Intestinal 1 
    Diffuse/Mixed 1.470 (1.264-1.708) 
Tumor location    0.202
    UB/Whole 1 ( 
    MB/LB 1.135 (0.934-1.378) 
MSI/MMR  0.290
    MSS/pMMR 1 ( 
    MSI-H/dMMR 1.155 (0.885-1.506) 
Adjuvant CTx  0.176
    No 1 ( 
    Yes 0.894 (0.760-1.052) 
Interval to recurrence (yr)  < 0.001
    < 1 1 ( 
    ≥ 1, < 2 0.768 (0.647-0.912) 0.003
    ≥ 2 0.650 (0.545-0.776) < 0.001
Type of recurrence  < 0.001
    Locoregional 1 ( 
    Hematogenous 1.010 (0.793-1.288) 0.935
    Peritoneum 1.434 (1.163-1.768) 0.001
    Any combination 1.603 (1.256-2.045) < 0.001
    Krukenberg only 0.614 (0.393-0.961) 0.033
CTx after recurrence  < 0.001
    No 1 ( 
    Yes 0.363 (0.306-0.431) 
HR, hazard ratio; CI, confidence interval; LN, lymph node; UB, upper body; MB, mid-body; LB, lower body; MSI, microsatellite instabil-
ity; MMR, mismatch repair; MSS, microsatellite stable; pMMR, proficient mismatch repair; MSI-H, microsatellite instability high; dMMR, 
deficient mismatch repair; CTx, chemotherapy. a)Adjusted by institution.
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received chemotherapy only after recurrence had the long-
est SAR (Table 4), and the prognosis of patients who received 
adjuvant chemotherapy was similar regardless of whether 
they did or did not receive chemotherapy after recurrence 
(log-rank p=0.020) (Fig. 1C). Similar findings were observed 
in the Y-cohort (log-rank p=0.080) and S-cohort (log-rank 
p=0.053) (S7A and S7B Fig.).  
Discussion
This study investigated the prognostic factors of patients 
with recurrent gastric cancer and the role of the MSI sta-
tus as a prognostic and predictive biomarker of SAR. We 
found that among patients with MSI-H/dMMR recurrent 
gastric cancer, treatment response to chemotherapy after 
recurrence differed according to whether or not the patient 
received adjuvant chemotherapy. To the best of our knowl-
edge, this is the first study to report such a result. This find-
ing is clinically valuable because chemotherapy in the adju-
vant setting would be detrimental to patients with stage II/
III MSI-H/dMMR gastric cancer when they develop tumor 
recurrence. Given that patients with MSI-H/dMMR stage 
II/III gastric cancer generally have favorable prognosis and 
that adjuvant/perioperative chemotherapy yields no ben-
efit in reducing the risk of tumor recurrence [4,11,12], these 
patients should be spared from adjuvant chemotherapy, 
with surgery alone being the most effective treatment strat-
egy. This finding may be due to the acquired resistance from 
adjuvant chemotherapy and the negative effects of chemo-
therapy on patient immunity. The mechanism for this has 
been hypothesized as follows: (1) DNA-targeted cytotoxic 
chemotherapy increases treatment resistance in tumors lack-
ing MMR activity, causing the selection of resistant MMR-
deficient tumors, and this condition could increase genetic 
instability, heterogeneity, and selection of more invasive 
tumor cells [21]. Consequently, adjuvant chemotherapy 
for patients with MSI-H/dMMR gastric cancer could cause 
chemotherapy resistance without reducing the risk of tumor 
recurrence, and recurrence leads to poor prognosis. (2) MSI-
H/dMMR tumors are related to enriched immune cells that 
may be responsible for the suppression of residual micro-
metastases after surgery [22,23], and chemotherapy may 
induce immune suppression [24]. In addition, chemothera-
py may have a negative effect on immune surveillance, and 
the innate benefit from a hypermutated phenotype could be 
attenuated [12]. These negative effects of chemotherapy on 
the patient’s immunity could lead to poor prognosis after 
tumor recurrence.
Our findings could lead to a clinical dilemma because not 
all patients with MSI-H/dMMR can be cured via surgery 
alone, and a tangible clinical benefit could be expected from 
adjuvant treatment in some patients with high-risk MSI-H/
dMMR gastric cancer [13,25]. Because patients with MSI-H/
dMMR tumors are possible candidates for immune-check-
point inhibitor treatment [26,27], adjuvant immunotherapy 
would be a better strategy than conventional chemotherapy 
for this population. However, the superiority of adjuvant 
immunotherapy still needs to be verified. In addition, giv-
en that the prognosis of MSI-H/dMMR tumors could vary 
according to certain biomarkers [28,29], secondary biomark-
ers that can be used to guide adjuvant treatment for this spe-
Table 3.  Multivariable Cox proportional hazard model for survival after recurrence in the overall cohort 
 Adjusted HRa) (95% CI) p-value
TNM  0.049
    II 1 (  
    III 1.199 (1.001-1.435) 
Lauren classification  < 0.001
    Intestinal 1 ( 
    Diffuse/Mixed 1.515 (1.294-1.775) 
Interval to recurrence (yr)  < 0.001
    < 1 1 ( 
    ≥ 1, < 2 0.754 (0.631-0.902) 0.002
    ≥ 2 0.648 (0.539-0.778) < 0.001
Type of recurrencb)  < 0.001
    Locoregional/Hematogenous 1 ( 
    Peritoneum/Combination 1.326 (1.085-1.620) 0.006
    Krukenberg only 0.665 (0.416-1.061) 0.087
Chemotherapy after recurrence  < 0.001
    No 1 ( 
    Yes 0.367 (0.309-0.435) 
HR, hazard ratio; CI, confidence interval. a)Adjusted by institution, b)Variables were categorized into three according to having similar HRs.
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cific type of gastric cancer should be investigated [13].
In this study, SAR was not statistically different accord-
ing to the MSI/MMR status, but it differed according to the 
cohort. MSI-H was related to shorter SAR in the Y-cohort, 
while there was no difference in SAR between dMMR and 
pMMR patients in the S-cohort. This finding may be due to 
the following reasons: (1) the effect of chemotherapy might 
differ according to the MSI/MMR status, and the propor-
tion of patients receiving adjuvant chemotherapy and chem-
otherapy after recurrence differed significantly between the 
cohorts in this study. (2) The Y-cohort was derived from a 
consecutive cohort enrolled between 2000 and 2010, while 
the S-cohort was derived from molecular or biomarker stud-
ies conducted between 1995 and 2008. (3) The MSI/MMR 
status was assessed using different methods in the cohorts, 
i.e., PCR in the Y-cohort and IHC analysis in the S-cohort. 
In colorectal cancer, the association between the MSI/MMR 
status and prognosis after recurrence has been conflicting. A 
study on the molecular subtypes of colorectal cancer report-
ed worse survival after relapse in those with MSI-H type 
[30], while a study of two randomized clinical trials report-
ed longer SAR among patients with dMMR colon cancers 
[28] and attributed this to the difference in recurrence pat-
tern according to the MMR status (regional vs. distant type). 
A similar recurrence pattern of MSI-H/dMMR and MSS/
pMMR tumors in this study resulted in a similar SAR, and 
Fig. 1.  Kaplan-Meier curves for survival after recurrence according to receiving adjuvant chemotherapy and chemotherapy after recur-
rence. (A) Regardless of the MSI/MMR status. (B) MSS/pMMR tumor. (C) MSI-H/dMMR tumors in the overall cohort. MSI, microsatel-
lite instability; MRR, mismatch repair; MSS, microsatellite stable; pMMR, proficient MMR; MSI-H, MSI-high; dMMR, deficient MMR; n, 
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the effect of chemotherapy when administered before and 
after recurrence needs to be considered when evaluating 
the prognosis after recurrence according to the MSI/MMR 
status. Additional evidence is needed to determine whether 
the MSI/MMR status could be a useful biomarker even after 
tumor recurrence. 
Given that initial tumor stage, Lauren classification, inter-
val to recurrence, and type of recurrence were significantly 
related to SAR, these factors should be considered for pati-
ent stratification in clinical trials for recurrent gastric cancer. 
More advanced initial tumor stage may be related to more 
subclinical metastases and aggressive biologic behaviors 
that result in more progressive recurrence [14]. The dif-
fuse histology of gastric cancer is related to cancer stemness 
and being refractory to chemotherapy [6,8], and this could 
lead to shorter SAR. Tumors that recur at a longer interval 
from initial treatment may tend to behave in a more indo-
lent manner after recurrence. Peritoneal and combination 
recurrence would be less responsive to oral or intravenous 
chemotherapy and may yield a higher tumor burden that 
could cause shorter SAR. 
This study enrolled patients from the two largest gastric 
cancer-specialized centers in Korea. Considering the low 
prevalence of MSI-H/dMMR gastric cancer with its favo-
rable prognosis, this cohort may be the largest to date. In 
addition, this study is the first to evaluate the effects of both 
chemotherapy before and after recurrence according to SAR 
biomarkers of gastric cancer. However, there are also pos-
sible limitations of this study that need to be addressed. The 
effects of chemotherapy after recurrence were likely overes-
timated as some patients died before chemotherapy could be 
implemented after tumor recurrence. Moreover, the retro- 
spective design of this study and the different chemothera-
py regimens used for adjuvant chemotherapy and chemo-
therapy after recurrence made it difficult to conduct more 
subgroup analysis for the effect of chemotherapies before 
and after recurrence by MSI/MMR status, and it might be 
another limitation. Despite these limitations, our results pro- 
vide clinical insight into the behavior of MSI-H/dMMR 
gastric cancer in the setting of standard of care and provide 
instrumental information for deciding on the appropriate 
treatment strategy for recurrent gastric cancer.
In conclusion, chemotherapy only after recurrence yields 
high SAR in gastric cancer patients with MSI-H/dMMR. 
This shows that in MSI gastric cancer, only post-recurrence 
chemotherapy and not adjuvant chemotherapy is beneficial. 
Furthermore, TNM stage, Lauren classification, interval to 
recurrence, and type of recurrence are associated with SAR 
and should thus be considered when creating the treatment 
plan and designing clinical trials targeting recurrent gastric 
cancer.  
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Table 4.  Association between treatment and survival after recurrence in the overall cohort and by MSI/MMR status 
 Adjusted HRa) (95% CI) p-value
Overall  < 0.001
    Adj–/CAR+ 1 ( 
    Adj+/CAR+ 1.229 (0.947-1.596) 0.121
    Adj–/CAR– 2.820 (2.062-3.856) < 0.001
    Adj+/CAR– 3.583 (2.658-4.831) < 0.001
MSS/pMMR  < 0.001
    Adj–/CAR+ 1 ( 
    Adj+/CAR+ 1.133 (0.867-1.481) 0.359
    Adj–/CAR– 2.798 (2.012-3.890) < 0.001
    Adj+/CAR– 3.356 (2.464-4.570) < 0.001
MSI-H/dMMR  < 0.001
    Adj–/CAR+ 1 ( 
    Adj+/CAR+ 5.360 (1.472-19.517) 0.011
    Adj–/CAR– 4.491 (1.412-14.290) 0.011
    Adj+/CAR– 12.052 (3.065-47.391) < 0.001 
MSI, microsatellite instability; MMR, mismatch repair; HR, hazard ratio; CI, confidence interval; Adj, adjuvant chemotherapy; CAR, chem-
otherapy after recurrence; MSS, microsatellite stable; pMMR, proficient mismatch repair; MSI-H, microsatellite instability high; dMMR, 
deficient mismatch repair. a)Adjusted by age, sex, and institution.
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